1.Risk Factors of FEV 1 /FVC Decline in COPD Patients
Na Young KIM ; Deog Kyeom KIM ; Shinhee PARK ; Yong Il HWANG ; Hyewon SEO ; Dongil PARK ; Seoung Ju PARK ; Jin Hwa LEE ; Kwang Ha YOO ; Hyun Woo LEE
Journal of Korean Medical Science 2025;40(6):e32-
Background:
Factors influencing the decline in forced expiratory volume in one second (FEV1 )/forced vital capacity (FVC) for chronic obstructive pulmonary disease (COPD) progression remain uncertain. We aimed to identify risk factors associated with rapid FEV1 / FVC decline in patients with COPD.
Methods:
This multi-center observational study was conducted from January 2012 to December 2022. Eligible patients were monitored with symptoms, spirometric tests, and treatment patterns over 3 years. Rapid FEV1 /FVC decliners were defined as the quartile of patients exhibiting the highest annualized percentage decline in FEV1 /FVC.
Results:
Among 1,725 patients, 435 exhibited rapid FEV1 /FVC decline, with an annual change of −2.5%p (interquartile range, −3.5 to −2.0). Rapid FEV1 /FVC decliners exhibited lower body mass index (BMI), higher smoking rates, elevated post-bronchodilator (BD) FEV1 , higher post-BD FEV1 / FVC, and a lower prevalence of Staging of Airflow Obstruction by Ratio (STAR) stage IV. Rapid FEV1 /FVC decline was not linked to the annual exacerbation rate, but there was an association with symptom deterioration and FEV1 decline. In multivariable analyses, low BMI, current smoking, increased modified Medical Research Council dyspnoea score, low post-BD FEV1 , low STAR stage, high forced mid-expiratory flow (FEF 25-75% ), accelerated FEV1 decline, and not initiating dual BD therapy were identified as independent risk factors for rapid FEV1 /FVC decline.
Conclusion
We identified the risk factors for rapid FEV1 /FVC decline, including BMI, smoking, symptoms deterioration, FEV1 decline, and adherence to standard inhaler treatment. Our findings underscore the potential benefits of maintaining consistent use of long-acting beta-agonist/long-acting muscarinic antagonist even in the presence of worsening symptoms, in attenuating FEV1 /FVC decline.
2.Risk Factors of FEV 1 /FVC Decline in COPD Patients
Na Young KIM ; Deog Kyeom KIM ; Shinhee PARK ; Yong Il HWANG ; Hyewon SEO ; Dongil PARK ; Seoung Ju PARK ; Jin Hwa LEE ; Kwang Ha YOO ; Hyun Woo LEE
Journal of Korean Medical Science 2025;40(6):e32-
Background:
Factors influencing the decline in forced expiratory volume in one second (FEV1 )/forced vital capacity (FVC) for chronic obstructive pulmonary disease (COPD) progression remain uncertain. We aimed to identify risk factors associated with rapid FEV1 / FVC decline in patients with COPD.
Methods:
This multi-center observational study was conducted from January 2012 to December 2022. Eligible patients were monitored with symptoms, spirometric tests, and treatment patterns over 3 years. Rapid FEV1 /FVC decliners were defined as the quartile of patients exhibiting the highest annualized percentage decline in FEV1 /FVC.
Results:
Among 1,725 patients, 435 exhibited rapid FEV1 /FVC decline, with an annual change of −2.5%p (interquartile range, −3.5 to −2.0). Rapid FEV1 /FVC decliners exhibited lower body mass index (BMI), higher smoking rates, elevated post-bronchodilator (BD) FEV1 , higher post-BD FEV1 / FVC, and a lower prevalence of Staging of Airflow Obstruction by Ratio (STAR) stage IV. Rapid FEV1 /FVC decline was not linked to the annual exacerbation rate, but there was an association with symptom deterioration and FEV1 decline. In multivariable analyses, low BMI, current smoking, increased modified Medical Research Council dyspnoea score, low post-BD FEV1 , low STAR stage, high forced mid-expiratory flow (FEF 25-75% ), accelerated FEV1 decline, and not initiating dual BD therapy were identified as independent risk factors for rapid FEV1 /FVC decline.
Conclusion
We identified the risk factors for rapid FEV1 /FVC decline, including BMI, smoking, symptoms deterioration, FEV1 decline, and adherence to standard inhaler treatment. Our findings underscore the potential benefits of maintaining consistent use of long-acting beta-agonist/long-acting muscarinic antagonist even in the presence of worsening symptoms, in attenuating FEV1 /FVC decline.
3.Risk Factors of FEV 1 /FVC Decline in COPD Patients
Na Young KIM ; Deog Kyeom KIM ; Shinhee PARK ; Yong Il HWANG ; Hyewon SEO ; Dongil PARK ; Seoung Ju PARK ; Jin Hwa LEE ; Kwang Ha YOO ; Hyun Woo LEE
Journal of Korean Medical Science 2025;40(6):e32-
Background:
Factors influencing the decline in forced expiratory volume in one second (FEV1 )/forced vital capacity (FVC) for chronic obstructive pulmonary disease (COPD) progression remain uncertain. We aimed to identify risk factors associated with rapid FEV1 / FVC decline in patients with COPD.
Methods:
This multi-center observational study was conducted from January 2012 to December 2022. Eligible patients were monitored with symptoms, spirometric tests, and treatment patterns over 3 years. Rapid FEV1 /FVC decliners were defined as the quartile of patients exhibiting the highest annualized percentage decline in FEV1 /FVC.
Results:
Among 1,725 patients, 435 exhibited rapid FEV1 /FVC decline, with an annual change of −2.5%p (interquartile range, −3.5 to −2.0). Rapid FEV1 /FVC decliners exhibited lower body mass index (BMI), higher smoking rates, elevated post-bronchodilator (BD) FEV1 , higher post-BD FEV1 / FVC, and a lower prevalence of Staging of Airflow Obstruction by Ratio (STAR) stage IV. Rapid FEV1 /FVC decline was not linked to the annual exacerbation rate, but there was an association with symptom deterioration and FEV1 decline. In multivariable analyses, low BMI, current smoking, increased modified Medical Research Council dyspnoea score, low post-BD FEV1 , low STAR stage, high forced mid-expiratory flow (FEF 25-75% ), accelerated FEV1 decline, and not initiating dual BD therapy were identified as independent risk factors for rapid FEV1 /FVC decline.
Conclusion
We identified the risk factors for rapid FEV1 /FVC decline, including BMI, smoking, symptoms deterioration, FEV1 decline, and adherence to standard inhaler treatment. Our findings underscore the potential benefits of maintaining consistent use of long-acting beta-agonist/long-acting muscarinic antagonist even in the presence of worsening symptoms, in attenuating FEV1 /FVC decline.
4.Risk Factors of FEV 1 /FVC Decline in COPD Patients
Na Young KIM ; Deog Kyeom KIM ; Shinhee PARK ; Yong Il HWANG ; Hyewon SEO ; Dongil PARK ; Seoung Ju PARK ; Jin Hwa LEE ; Kwang Ha YOO ; Hyun Woo LEE
Journal of Korean Medical Science 2025;40(6):e32-
Background:
Factors influencing the decline in forced expiratory volume in one second (FEV1 )/forced vital capacity (FVC) for chronic obstructive pulmonary disease (COPD) progression remain uncertain. We aimed to identify risk factors associated with rapid FEV1 / FVC decline in patients with COPD.
Methods:
This multi-center observational study was conducted from January 2012 to December 2022. Eligible patients were monitored with symptoms, spirometric tests, and treatment patterns over 3 years. Rapid FEV1 /FVC decliners were defined as the quartile of patients exhibiting the highest annualized percentage decline in FEV1 /FVC.
Results:
Among 1,725 patients, 435 exhibited rapid FEV1 /FVC decline, with an annual change of −2.5%p (interquartile range, −3.5 to −2.0). Rapid FEV1 /FVC decliners exhibited lower body mass index (BMI), higher smoking rates, elevated post-bronchodilator (BD) FEV1 , higher post-BD FEV1 / FVC, and a lower prevalence of Staging of Airflow Obstruction by Ratio (STAR) stage IV. Rapid FEV1 /FVC decline was not linked to the annual exacerbation rate, but there was an association with symptom deterioration and FEV1 decline. In multivariable analyses, low BMI, current smoking, increased modified Medical Research Council dyspnoea score, low post-BD FEV1 , low STAR stage, high forced mid-expiratory flow (FEF 25-75% ), accelerated FEV1 decline, and not initiating dual BD therapy were identified as independent risk factors for rapid FEV1 /FVC decline.
Conclusion
We identified the risk factors for rapid FEV1 /FVC decline, including BMI, smoking, symptoms deterioration, FEV1 decline, and adherence to standard inhaler treatment. Our findings underscore the potential benefits of maintaining consistent use of long-acting beta-agonist/long-acting muscarinic antagonist even in the presence of worsening symptoms, in attenuating FEV1 /FVC decline.
5.A 4-Year Observation of the Incidence of Depressionand Suicide Among Older Adults from the Onset of theCOVID-19
Seoung-Kyun LEE ; Bo-Hyun YOON ; Kyungmin KIM ; Ha-Ran JUNG ; Hangoeunbi KANG ; Yuran JEONG ; Hyunju YUN ; Jye-Heon SONG ; Young-Hwa SEA ; Suhee PARK
Mood and Emotion 2023;21(3):51-60
Background:
This study aimed to examine the influence of the coronavirus disease pandemic 2019 (COVID-19) by comparing the incidences of depression, suicidal ideation, and suicidal attempts before and after the outbreak of the pandemic among community-dwelling older adults.
Methods:
In total, 9,784 older adults were recruited from 22 counties in Jeollanam-do between 2019 and 2022. Selfreported questionnaires, including sociodemographic factors, suicidal ideation, suicidal attempt, and Geriatric Depression Scale-Short Form Korean version, were used.
Results:
The proportion of the depression high-risk group tended to increase since the COVID-19 outbreak, increasing to 16.3%, 23.1%, and 25.7% in 2019, 2020, and 2021, respectively; however, decreased to 21.8% in 2022. The incidence of suicidal ideation showed a similar pattern. The incidence of suicidal attempts showed a different pattern, rising to 1.3% and 2.6% in 2019 and 2020, respectively and then falling to 1.1% and 0.8% in 2021 and 2022, respectively.
Conclusion
This study examined community-dwelling older adults and their mental states during the COVID-19 pandemic, and found that the risk of depression among older adults increased 1.708-fold in 2020, 1.877-fold in 2021, and 1.599-fold in 2022 compared to that in 2019, the year before the pandemic. Similarly, the risk of suicidal ideation increased by 1.582-fold in 2020, 1.913-fold in 2021, and 1.623-fold in 2022 compared with 2019 data. As the pandemic extended, mental health states improved; however, not to prepandemic levels. Suggesting that older people need continued support to alleviate the negative effects of the COVID-19 pandemic.
6.The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106).
Boram HA ; Kwan Ho CHO ; Sung Ho MOON ; Chang Geol LEE ; Ki Chang KEUM ; Yeon Sil KIM ; Hong Gyun WU ; Jin Ho KIM ; Yong Chan AHN ; Dongryul OH ; Jae Myoung NOH ; Jong Hoon LEE ; Sung Hwan KIM ; Won Taek KIM ; Young Taek OH ; Min Kyu KANG ; Jin Hee KIM ; Ji Yoon KIM ; Moon June CHO ; Chul Seoung KAY ; Jin Hwa CHOI
Cancer Research and Treatment 2019;51(1):12-23
PURPOSE: The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS). RESULTS: At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170). CONCLUSION: A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.
Cohort Studies
;
Disease-Free Survival
;
Education
;
Follow-Up Studies
;
Humans
;
Nasopharyngeal Neoplasms
;
Radiotherapy
;
Radiotherapy, Intensity-Modulated
;
Retrospective Studies*
;
Treatment Outcome
7.Endovascular Coiling for a Wide-neck Bifurcated Aneurysm with Anterograde Horizontal Stenting via Microcatheter Looping: A Technical Case Report.
Hyun Jae JEON ; Jong Hwa PARK ; Jong Young LEE ; Hong Jun JEON ; Seoung Woo PARK ; Byung Moon CHO
Journal of Cerebrovascular and Endovascular Neurosurgery 2018;20(3):181-186
Technical advances with devices such as catheters, balloons, and stents have widened the indications for endovascular coiling for unfavorable aneurysms. The authors report two cases of coil embolization for a wide-neck bifurcated aneurysm with anterograde horizontal stenting via microcatheter looping. Two women, aged 56 and 38 years, respectively, had an undertall- and overwide-neck aneurysm with bifurcated branches at the basilar bifurcation and middle cerebral bifurcation, respectively. The delivery microcatheter was steamed so that it could be looped deliberately to the opposite vessel. The enterprise stent was first anchored to the vessel of the posterior cerebral artery on one side. The remaining portion was spanned into a looped microcatheter to the opposite branch while pushing the stent. The Neuroform Atlas stent was passed directly through the looped segment of the microcatheter at the M2 branch and spanned horizontally by unsheathing. Under horizontal stenting, complete coil embolization was achieved without immediate or delayed complications in both cases. This novel technique presents a viable option for stent-assisted coiling within an optimal anatomy.
Aneurysm*
;
Catheters
;
Embolization, Therapeutic
;
Female
;
Humans
;
Intracranial Aneurysm
;
Posterior Cerebral Artery
;
Steam
;
Stents*
8.Effects of Rainfall on Microbial Water Quality on Haeundae and Gwangan Swimming Beach.
Seoung Hwa CHOI ; Seung Min LEE ; Gyeong Seon KIM ; Mi Hee KIM ; Hwa Seong JI ; Yu Na JEONG ; Eun Chul YOO ; Jeong Gu CHO
Journal of Bacteriology and Virology 2016;46(2):71-83
The associations between storm events, urban runoff and costal water quality have not been well investigated in Korea. A temporal and spatial analysis during summer, 2015 was conducted to determine associates between urban runoff and fecal indicator bacteria (Escherichia coli, Enterococcus) levels at two popular coastal beaches (Gwanganri beach and Haundae beach) in Busan. In this study, a clear relationship between rainfall and elevated number of indicators was observed. Two beaches met the costal beach water health standards after less than 3.0 mm of rain. Only for storms less than 2.5 mm was no observable rainfall effect. Our results revealed that exceedances were greatest in 5 hours following 41.0~45.5 rainfall, then declined the bacterial concentrations in 8 hours after the storm and they generally returned to levels below water health standards within 10~14 hours. But it took 2.7 days to get the level of water quality of dry days. The time required for water quality recovery depends on the intensity and duration of rainfall. In the event of intense rainfall issuance of beach closure by public authorities is warranted to protect public health.
Bacteria
;
Busan
;
Enterococcus
;
Korea
;
Public Health
;
Rain
;
Spatial Analysis
;
Swimming*
;
Water Quality*
;
Water*
9.A Novel Synthetic Mycolic Acid Inhibits Bronchial Hyperresponsiveness and Allergic Inflammation in a Mouse Model of Asthma.
Young Joon KIM ; Ha Jung KIM ; Se Kyoo JEONG ; Seung Hwa LEE ; Mi Jin KANG ; Ho Sung YU ; Young Ho JUNG ; Ju Hee SEO ; Byoung Ju KIM ; Jinho YU ; Seoung Ju PARK ; Yong Chul LEE ; Soo Jong HONG
Allergy, Asthma & Immunology Research 2014;6(1):83-88
PURPOSE: Recognition of microbes is important to trigger the innate immune system. Mycolic acid (MA) is a component of the cell walls of mycobacteria such as Mycobacterium bovis Bacillus Calmette-Guerin. MA has immunogenic properties, which may modulate the innate and adaptive immune response. This study aimed to investigate whether a novel synthetic MA (sMA) inhibits allergic inflammatory responses in a mouse model of asthma. METHODS: BALB/c mice were injected intraperitoneally with sMA followed by sensitization and challenge with ovalbumin (OVA). Mice were examined for bronchial hyperresponsiveness (BHR), the influx of inflammatory cells into the lung tissues, histopathological changes in the lungs and CD4+CD25+Foxp3+ T cells in the spleen, and examined the response after the depleting regulatory T cells (Tregs) with an anti-CD25mAb. RESULTS: Treatment of mice with sMA suppressed the asthmatic response, including BHR, bronchoalveolar inflammation, and pulmonary eosinophilic inflammation. Anti-CD25mAb treatment abrogated the suppressive effects of sMA in this mouse model of asthma and totally depleted CD4+CD25+Foxp3+ T cells in the spleen. CONCLUSIONS: sMA attenuated allergic inflammation in a mouse model of asthma, which might be related with CD4+CD25+Foxp3+ T cell.
Adaptive Immunity
;
Animals
;
Asthma*
;
Bacillus
;
Cell Wall
;
Eosinophils
;
Immune System
;
Inflammation*
;
Lung
;
Mice*
;
Mycobacterium bovis
;
Mycolic Acids*
;
Ovalbumin
;
Spleen
;
T-Lymphocytes
;
T-Lymphocytes, Regulatory
10.Genetic populations of Bacillus anthracis isolates from Korea.
Kyoung Hwa JUNG ; Sang Hoon KIM ; Se Kye KIM ; Soo Young CHO ; Jin Choul CHAI ; Young Seek LEE ; Ji Cheon KIM ; Seoung Joo KIM ; Hee Bok OH ; Young Gyu CHAI
Journal of Veterinary Science 2012;13(4):385-393
Bacillus (B.) anthracis is the pathogen that causes fatal anthrax. Strain-specific detection of this bacterium using molecular approaches has enhanced our knowledge of microbial population genetics. In the present study, we employed molecular approaches including multiple-locus variable-number tandem repeat analysis (MLVA) and canonical single-nucleotide polymorphism (canSNP) analysis to perform molecular typing of B. anthracis strains isolated in Korea. According to the MLVA, 17 B. anthracis isolates were classified into A3a, A3b, and B1 clusters. The canSNP analyses subdivided the B. anthracis isolates into two of the three previously recognized major lineages (A and B). B. anthracis isolates from Korea were found to belong to four canSNP sub-groups (B.Br.001/2, A.Br.005/006, A.Br.001/002, and A.Br.Ames). The A.Br.001/002 and A.Br.Ames sub-lineages are closely related genotypes frequently found in central Asia and most isolates were. On the other hand, B. anthracis CH isolates were analyzed that belonged to the B.Br.001/002 sub-group which found in southern Africa, Europe and California (USA). B.Br.001/002 genotype is new lineage of B. anthracis in Korea that was not found before. This discovery will be helpful for the creation of marker systems and might be the result of human activity through the development of agriculture and increased international trade in Korea.
Africa, Southern
;
Agriculture
;
Anthrax
;
Asia
;
Bacillus
;
Bacillus anthracis
;
California
;
Europe
;
Genetics, Population
;
Genotype
;
Hand
;
Human Activities
;
Molecular Typing
;
Tandem Repeat Sequences

Result Analysis
Print
Save
E-mail